Conditioning regimens
| Conditioning regimen . | No. of patients . |
|---|---|
| Fludarabine (90 mg/m2) + melphalan (100-140 mg/m2) ± ATG | 15 |
| Thiotepa (10 mg/kg) + cyclophosphamide (100 mg/kg) ± ATG | 11 |
| Fludarabine (60 mg/m2) + cyclophosphamide (60 mg/kg) + thiotepa (10 mg/kg) | 49 |
| Fludarabine (150 mg/m2) + busulfan (8 mg/kg) | 2 |
| Thiotepa (5 mg/kg) + cyclophosphamide (100 mg/kg) + melphalan (70 mg/m2) + ATG or alemtuzumab | 6 |
| Fludarabine (120 mg/m2) + cyclophosphamide (60 mg/kg) + thiotepa (10 mg/kg) + alemtuzumab + TBI 2 Gy | 6 |
| Fludarabine (120 mg/m2) + cyclophosphamide (900 mg/m2) | 11 |
| Fludarabine (90 mg/m2) + TBI 2 Gy | 4 |
| Conditioning regimen . | No. of patients . |
|---|---|
| Fludarabine (90 mg/m2) + melphalan (100-140 mg/m2) ± ATG | 15 |
| Thiotepa (10 mg/kg) + cyclophosphamide (100 mg/kg) ± ATG | 11 |
| Fludarabine (60 mg/m2) + cyclophosphamide (60 mg/kg) + thiotepa (10 mg/kg) | 49 |
| Fludarabine (150 mg/m2) + busulfan (8 mg/kg) | 2 |
| Thiotepa (5 mg/kg) + cyclophosphamide (100 mg/kg) + melphalan (70 mg/m2) + ATG or alemtuzumab | 6 |
| Fludarabine (120 mg/m2) + cyclophosphamide (60 mg/kg) + thiotepa (10 mg/kg) + alemtuzumab + TBI 2 Gy | 6 |
| Fludarabine (120 mg/m2) + cyclophosphamide (900 mg/m2) | 11 |
| Fludarabine (90 mg/m2) + TBI 2 Gy | 4 |
ATG or alemtuzumab has been used in matched-unrelated or haploidentical donors.
ATG indicates antithymocyte globulin; and TBI, total body irradiation.